Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure - The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF)
Autore:
Hjalmarson, A; Goldstein, S; Fagerberg, B; Wedel, H; Waagstein, F; Kjekshus, J; Wikstrand, J; El Allaf, D; Vitovec, J; Aldershvile, J; Halinen, M; Dietz, R; Neuhaus, KL; Janosi, A; Thorgeirsson, G; Dunselman, PHJM; Gullestad, L; Kuch, J; Herlitz, J; Rickenbacher, P; Ball, S; Gottlieb, S; Deedwania, P;
Indirizzi:
Sahlgrens Univ Hosp, Wallenberg Lab Cardiovasc Res, SE-41345 Gothenburg, Sweden Sahlgrens Univ Hosp Gothenburg Sweden SE-41345 -41345 Gothenburg, Sweden Sahlgrens Univ Hosp, Dept Cardiol, SE-41345 Gothenburg, Sweden Sahlgrens Univ Hosp Gothenburg Sweden SE-41345 -41345 Gothenburg, Sweden Nord Sch Publ Hlth, Gothenburg, Sweden Nord Sch Publ Hlth Gothenburg Sweden Sch Publ Hlth, Gothenburg, Sweden Henry Ford Hosp, Detroit, MI 48202 USA Henry Ford Hosp Detroit MI USA 48202 nry Ford Hosp, Detroit, MI 48202 USA Univ Oslo, Rikshosp, Dept Med, N-0027 Oslo, Norway Univ Oslo Oslo NorwayN-0027 lo, Rikshosp, Dept Med, N-0027 Oslo, Norway Baerums Sykehus, Baerum, Norway Baerums Sykehus Baerum NorwayBaerums Sykehus, Baerum, Norway Ctr Hosp Hutois, Serv Cardiol & Reanimat Cardiaque, Huy, Belgium Ctr Hosp Hutois Huy Belgium Cardiol & Reanimat Cardiaque, Huy, Belgium Fak Nemocnice, Interni Klin 2, Brno, Czech Republic Fak Nemocnice Brno Czech Republic Interni Klin 2, Brno, Czech Republic Rigshosp, Dept Med B, DK-2100 Copenhagen, Denmark Rigshosp Copenhagen Denmark DK-2100 t Med B, DK-2100 Copenhagen, Denmark Kuopio Univ Hosp, Dept Accid & Emergency, SF-70210 Kuopio, Finland Kuopio Univ Hosp Kuopio Finland SF-70210 gency, SF-70210 Kuopio, Finland Franz Volhard Klin, Berlin, Germany Franz Volhard Klin Berlin GermanyFranz Volhard Klin, Berlin, Germany Klinikum Kassel, Med Klin 2, Kassel, Germany Klinikum Kassel Kassel Germany ikum Kassel, Med Klin 2, Kassel, Germany Szent Janos Hosp, Budapest, Hungary Szent Janos Hosp Budapest HungarySzent Janos Hosp, Budapest, Hungary Univ Hosp, Landspitalinn, Dept Med, Reykjavik, Iceland Univ Hosp Reykjavik Iceland Landspitalinn, Dept Med, Reykjavik, Iceland St Ignatius Ziekenhuis, Dept Cardiol, Breda, Netherlands St Ignatius Ziekenhuis Breda Netherlands pt Cardiol, Breda, Netherlands Warsaw Sch Med, Dept Cardiol, Warsaw, Poland Warsaw Sch Med Warsaw Poland rsaw Sch Med, Dept Cardiol, Warsaw, Poland Kantonsspital Bruderholz, Bruderholz, Switzerland Kantonsspital Bruderholz Bruderholz Switzerland Bruderholz, Switzerland Leeds Gen Infirm, Inst Cardiovasc Res, Leeds, W Yorkshire, England Leeds Gen Infirm Leeds W Yorkshire England , Leeds, W Yorkshire, England Univ Maryland, Div Cardiol, Baltimore, MD 21201 USA Univ Maryland Baltimore MD USA 21201 Div Cardiol, Baltimore, MD 21201 USA Dept Vet Affairs Med Ctr, Fresno, CA USA Dept Vet Affairs Med Ctr Fresno CA USA t Affairs Med Ctr, Fresno, CA USA
Titolo Testata:
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
fascicolo: 10, volume: 283, anno: 2000,
pagine: 1295 - 1302
SICI:
0098-7484(20000308)283:10<1295:EOCMOT>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
CLINICAL-TRIALS; DOUBLE-BLIND; CARVEDILOL; QUESTIONNAIRE; MORBIDITY; BLOCKADE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Fagerberg, B Sahlgrens Univ Hosp, Wallenberg Lab Cardiovasc Res, SE-41345 Gothenburg, Sweden Sahlgrens Univ Hosp Gothenburg Sweden SE-41345 burg, Sweden
Citazione:
A. Hjalmarson et al., "Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure - The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF)", J AM MED A, 283(10), 2000, pp. 1295-1302

Abstract

Context Results from recent studies on the effects of beta(1)-blockade in patients with heart failure demonstrated a 34% reduction in total mortality. However, the effect of beta(1)-blockade on the frequency of hospitalizations, symptoms, and quality of life in patients with heart failure has not been fully explored. Objective To examine the effects of the beta(1)-blocker controlled-release/extended-release metoprolol succinate (metoprolol CR/XL) on mortality, hospitalization, symptoms, and quality of life in patients with heart failure. Design Randomized, double-blind controlled trial, preceded by a 2-week single-blind placebo run-in period, conducted from February 14, 1997, to October 31, 1998, with a mean follow-up of 1 year. Setting Three hundred thirteen sites in 14 countries. Participants Patients (n = 3991) with chronic heart failure, New York Heart Association (NYHA) functional class II to IV, and election fraction of 0.40 or less who were stabilized with optimum standard therapy. Interventions Patients were randomized to metoprolol CR/XL, 25 mg once perday (NYHA class II), or 12.5 mg once per day (NYHA class III or IV), titrated for 6 to 8 weeks up to a target dosage of 200 mg once per day (n = 1990); or matching placebo (n = 2001). Main Outcome Measures Total mortality or any hospitalization (time to first event), number of hospitalizations for worsening heart failure, and change in NYHA class, by intervention group; quality of life was assessed in a substudy of 741 patients. Results The incidence of all predefined end points was lower in the metoprolol CR/XL group than in the placebo group, including total mortality or all-cause hospitalizations (the prespecified second primary end point; 641 vs767 events; risk reduction, 19%; 95% confidence interval [CI], 10%-27%; P<.001); total mortality or hospitalizations due to worsening heart failure (311 vs 439 events; risk reduction, 31%; 95% CI, 20%-40%; P<.001), number ofhospitalizations due to worsening heart failure (317 vs 451; P<.001); and number of days in hospital due to worsening heart failure (3401 vs 5303 days; P<.001). NYHA functional class, assessed by physicians, and McMaster Overall Treatment Evaluation score, assessed by patients, both improved in themetoprolol CR/XL group compared with the placebo group (P = .003 and P = .009, respectively). Conclusions In this study of patients with symptomatic heart failure, metoprolol CR/XL improved survival, reduced the need for hospitalizations due to worsening heart failure, improved NYHA functional class, and had beneficial effects on patient well-being.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 00:21:52